Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozuleristide for Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma
NCT05316688Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tozuleristide in oral cavity squamous cell carcinoma (OCSCC) and oral epithelial dysplasia (OED), sponsored by University of Washington. Primary endpoint: Number of Adverse Events. Started Apr 2024; status: terminated.
02
Drugs
tozuleristide
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)oral epithelial dysplasia (OED)
Beyond the preview
Go deeper on NCT05316688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316688.